The Stock Day Podcast welcomed Ensysce Biosciences (Nasdaq:ENSC)(“the Company”), a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. CEO of the Company, Dr. Lynn Kirkpatrick, joined Stock Day host Matthew Dunehoo. Dunehoo began the interview...
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a second closing pursuant to its previously announced private placement of units of the Company. Pursuant to the second closing, the Company issued 1,596,830 units of the Company...
The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ:TCBP)(“the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the that it has been awarded a $750,000 grant from the Army Medical Research...
The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB:BLGO), a cleantech and life sciences innovator and engineering services solution provider. President and CEO of BioLargo, Inc., Dennis P. Calvert, joined Stock Day host Kevin Davis. The interview covered the following topics: The company’s...
QUÉBEC CITY, Dec. 22, 2022 /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ QUÉBEC CITY, Dec. 22, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS)...
Company recorded a record high of $12 million in quarterly revenue (84% YoY increase) and Net Income of $2.6 million Full year revenues were $36 million, a 108% increase compared to 2021 Delivered its sixth consecutive quarter of positive Adjusted EBITDA of $2.5M, and $5.3M for fiscal year 2022...
MONTREAL, Aug. 2, 2022 Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugs Acquisition allows Valeo to expand into Ophthalmology and Allergy Licensing transactions to more than double Valeo's annual revenues Provides financial flexibility to accelerate growth and...
IR-Med (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technologies, announced that it has entered into a Subscription Agreements with certain investors for...